https://www.businesswire.com/news/home/20251013594159/en/Zai-Lab-Announces-Oral-Presentation-of-Updated-Data-from-Global-Phase-1-Trial-of-Zocilurtatug-Pelitecan-ZL-1310-a-Potential-First-in-Class-DLL3-Targeted-ADC-at-2025-AACR-NCI-EORTC-Conference
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT...